Targeting angiogenesis in chronic liver diseases with portal hypertension: anti–placenta growth factor inhibitor or multikinase inhibitor sorafenib?
暂无分享,去创建一个
O. Mir | F. Goldwasser | S. Pol | R. Coriat | S. Chaussade
[1] S. Alavian,et al. Commentary on emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy , 2011, Hepatology.
[2] R. Andrade,et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. , 2011, Journal of hepatology.
[3] K. Glaser,et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis , 2011, Hepatology.
[4] C. Yeh,et al. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy , 2011, Hepatology.
[5] Suihai Wang,et al. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway , 2011, Hepatology.
[6] P. Carmeliet,et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice , 2011, Hepatology.
[7] M. Pack,et al. DNA hypomethylation causes bile duct defects in zebrafish and is a distinguishing feature of infantile biliary atresia , 2011, Hepatology.
[8] O. Mir,et al. Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib , 2011, PloS one.
[9] T. Yeh,et al. Hepatitis B virus–DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma , 2010, Hepatology.
[10] J. Talwalkar,et al. Drug‐induced autoimmune hepatitis: Clinical characteristics and prognosis , 2010, Hepatology.
[11] American Type Culture Collection Standards Development Orga ASN-0002. Cell line misidentification: the beginning of the end , 2010, Nature Reviews Cancer.
[12] D. Houlihan,et al. Critical review of clinical trials of bone marrow stem cells in liver disease. , 2008, Gastroenterology.
[13] N. Warner,et al. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound , 2008, Hepatology.
[14] R. Virmani,et al. A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. , 2007, European heart journal.
[15] Roland M. Nardone,et al. Eradication of cross-contaminated cell lines: A call for action , 2007, Cell Biology and Toxicology.
[16] D. Prockop,et al. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. , 2007, Blood.
[17] Y. Liaw,et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. , 2007, Gastroenterology.
[18] L. Claesson‐Welsh,et al. VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.
[19] Kai-yun Chen,et al. [A preliminary study of the homing capacity of allograft mesenchymal stem cells to rat liver]. , 2005, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.
[20] Stefan Schmidt,et al. Cancer cell line identification by short tandem repeat profiling: power and limitations , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] C. Gartung,et al. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. , 2002, The New England journal of medicine.
[22] Chien-Jen Chen,et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.
[23] N. Terrault,et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort , 2001, Hepatology.
[24] J. Golmard,et al. Epidemiology of biliary atresia in France: a national study 1986-96. , 1999, Journal of hepatology.
[25] M. Manns,et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. , 1999, Journal of hepatology.
[26] C. Chu,et al. Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B. , 1998, The Journal of infectious diseases.
[27] M. Khoury,et al. Epidemiology of biliary atresia: a population-based study. , 1997, Pediatrics.
[28] L. Mimms,et al. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA , 1995, The Lancet.
[29] L. Mimms,et al. Hepatitis B virus escape mutants: “pushing the envelope” of chronic hepatitis B virus infection , 1995, Hepatology.
[30] H. Okamoto,et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen , 1994, Journal of virology.
[31] K. Shannon,et al. Studies in the etiology of extrahepatic biliary atresia: time-space clustering. , 1982, The Journal of pediatrics.
[32] W. Nelson-Rees,et al. HeLa cultures defined. , 1976, Science.
[33] J. Snyder,et al. Continuous Subcultivation of Epithelial-like Cells from Normal Human Tissues.∗ , 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[34] B. Ure,et al. Prevention of biliary atresia in the experimental mouse model provides a new approach to elucidate its immune pathomechanism. , 2010, Journal of Pediatric Surgery.
[35] Norman Gitlin,et al. Chronic hepatitis B : an update , 2010 .
[36] C. Yeh. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. , 2010, Antiviral therapy.
[37] M. Lacroix,et al. Persistent use of “false” cell lines , 2008, International journal of cancer.
[38] Zhu Chang-l. Dose-Dependent Relationship of Bone Marrow Mesenchymal Stem Cells Transplantation to Cardiomyogenesis for Functional Regenerative Recovery after Myocardial Infarction , 2007 .
[39] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.